First Time Loading...

argenx SE
NASDAQ:ARGX

Watchlist Manager
argenx SE Logo
argenx SE
NASDAQ:ARGX
Watchlist
Price: 371.92 USD 0.9% Market Closed
Updated: Apr 27, 2024

Intrinsic Value

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. [ Read More ]

The intrinsic value of one ARGX stock under the Base Case scenario is 482.96 USD. Compared to the current market price of 371.92 USD, argenx SE is Undervalued by 23%.

Key Points:
ARGX Intrinsic Value
Base Case
482.96 USD
Undervaluation 23%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
argenx SE

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ARGX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
argenx SE

Provide an overview of the primary business activities
of argenx SE.

What unique competitive advantages
does argenx SE hold over its rivals?

What risks and challenges
does argenx SE face in the near future?

Summarize the latest earnings call
of argenx SE.

What significant events have occurred
in argenx SE over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for argenx SE.

Provide P/S
for argenx SE.

Provide P/E
for argenx SE.

Provide P/OCF
for argenx SE.

Provide P/FCFE
for argenx SE.

Provide P/B
for argenx SE.

Provide EV/S
for argenx SE.

Provide EV/GP
for argenx SE.

Provide EV/EBITDA
for argenx SE.

Provide EV/EBIT
for argenx SE.

Provide EV/OCF
for argenx SE.

Provide EV/FCFF
for argenx SE.

Provide EV/IC
for argenx SE.

Show me price targets
for argenx SE made by professional analysts.

What are the Revenue projections
for argenx SE?

How accurate were the past Revenue estimates
for argenx SE?

What are the Net Income projections
for argenx SE?

How accurate were the past Net Income estimates
for argenx SE?

What are the EPS projections
for argenx SE?

How accurate were the past EPS estimates
for argenx SE?

What are the EBIT projections
for argenx SE?

How accurate were the past EBIT estimates
for argenx SE?

Compare the revenue forecasts
for argenx SE with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of argenx SE and its key competitors using the latest financial data.

Compare historical revenue growth rates
of argenx SE against its competitors.

Analyze the profit margins
(gross, operating, and net) of argenx SE compared to its peers.

Compare the P/E ratios
of argenx SE against its peers.

Discuss the investment returns and shareholder value creation
comparing argenx SE with its peers.

Analyze the financial leverage
of argenx SE compared to its main competitors.

Show all profitability ratios
for argenx SE.

Provide ROE
for argenx SE.

Provide ROA
for argenx SE.

Provide ROIC
for argenx SE.

Provide ROCE
for argenx SE.

Provide Gross Margin
for argenx SE.

Provide Operating Margin
for argenx SE.

Provide Net Margin
for argenx SE.

Provide FCF Margin
for argenx SE.

Show all solvency ratios
for argenx SE.

Provide D/E Ratio
for argenx SE.

Provide D/A Ratio
for argenx SE.

Provide Interest Coverage Ratio
for argenx SE.

Provide Altman Z-Score Ratio
for argenx SE.

Provide Quick Ratio
for argenx SE.

Provide Current Ratio
for argenx SE.

Provide Cash Ratio
for argenx SE.

What is the historical Revenue growth
over the last 5 years for argenx SE?

What is the historical Net Income growth
over the last 5 years for argenx SE?

What is the current Free Cash Flow
of argenx SE?

Discuss the annual earnings per share (EPS)
trend over the past five years for argenx SE.

Financials

Balance Sheet Decomposition
argenx SE

Current Assets 4.1B
Cash & Short-Term Investments 3.2B
Receivables 499.3m
Other Current Assets 444.6m
Non-Current Assets 418.7m
Long-Term Investments 47.2m
PP&E 22.7m
Intangibles 125.2m
Other Non-Current Assets 223.7m
Current Liabilities 423m
Accounts Payable 245.6m
Accrued Liabilities 150.9m
Other Current Liabilities 26.5m
Non-Current Liabilities 22m
Long-Term Debt 15.4m
Other Non-Current Liabilities 6.6m
Efficiency

Earnings Waterfall
argenx SE

Revenue
1.2B USD
Cost of Revenue
-117.8m USD
Gross Profit
1.1B USD
Operating Expenses
-1.5B USD
Operating Income
-420.6m USD
Other Expenses
125.6m USD
Net Income
-295.1m USD

Free Cash Flow Analysis
argenx SE

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

ARGX Profitability Score
Profitability Due Diligence

argenx SE's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
37/100
Profitability
Score

argenx SE's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

ARGX Solvency Score
Solvency Due Diligence

argenx SE's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
75/100
Solvency
Score

argenx SE's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ARGX Price Targets Summary
argenx SE

Wall Street analysts forecast ARGX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ARGX is 511.07 USD with a low forecast of 391.03 USD and a high forecast of 677.53 USD.

Lowest
Price Target
391.03 USD
5% Upside
Average
Price Target
511.07 USD
37% Upside
Highest
Price Target
677.53 USD
82% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

ARGX Price
argenx SE

1M 1M
-6%
6M 6M
-21%
1Y 1Y
+1%
3Y 3Y
+44%
5Y 5Y
+205%
10Y 10Y
+4 276%
Annual Price Range
345.7
52w Low
298.7
52w High
491.8
Price Metrics
Average Annual Return 34.31%
Standard Deviation of Annual Returns 24.77%
Max Drawdown -39%
Shares Statistics
Market Capitalization 20.5B EUR
Shares Outstanding 59 194 488
Percentage of Shares Shorted
N/A

ARGX Return Decomposition
Main factors of price return

What is price return decomposition?

ARGX News

Other Videos

Last Important Events
argenx SE

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
argenx SE

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

argenx SE Logo
argenx SE

Country

Netherlands

Industry

Biotechnology

Market Cap

20.5B USD

Dividend Yield

0%

Description

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. The company is headquartered in Breda, Noord-Brabant and currently employs 650 full-time employees. The company went IPO on 2014-07-10. The company creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.

Contact

NOORD-BRABANT
Breda
Willemstraat 5
+31763030488.0
https://www.argenx.com/

IPO

2014-07-10

Employees

650

Officers

CEO & Executive Director
Mr. Timothy Van Hauwermeiren EMBA, M.B.A., M.Sc.
Chief Financial Officer
Mr. Karl Gubitz
Chief Operating Officer
Ms. Karen Massey
VP & Global Head of Technical Operations
Mr. Filip Borgions
Chief Scientific Officer
Mr. Peter Ulrichts
VP and Global Head of Corporate Communications & Investor Relations
Ms. Beth DelGiacco
Show More
General Counsel
Ms. Malini Moorthy
Vice President of Corporate Development & Strategy
Mr. Arjen Lemmen M.Sc.
Global Head of Human Resources
Mr. Marc Schorpion
Global Head of Quality
Ms. Andria Wilk
Show Less

See Also

Discover More
What is the Intrinsic Value of one ARGX stock?

The intrinsic value of one ARGX stock under the Base Case scenario is 482.96 USD.

Is ARGX stock undervalued or overvalued?

Compared to the current market price of 371.92 USD, argenx SE is Undervalued by 23%.